ZVRA Q2 2025 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+481.7% YoY

Gross Profit

$14M52.2% margin

Operating Income

-$71M-274.5% margin

Net Income

$75M288.7% margin

EPS (Diluted)

$1.36

QoQ Revenue Growth

+26.9%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$256M

Total Liabilities

$139M

Stockholders' Equity

$117M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$4M	+481.7%
Gross Profit	$14M	$876,000	+1441.3%
Operating Income	-$71M	-$24M	-198.5%
Net Income	$75M	-$20M	+474.9%